This is supported by recent studies from US and German adults with T2D, which reported that the use of GLP-1RAs versus insulin resulted in lower emergency room visits and inpatient admissions but higher drug acquisition costs after treatment initiation [49, 50]. The gene discussed is INS; the disease is type 2 diabetes mellitus.